Literature DB >> 16930530

Lipoplexes formed from sugar-based gemini surfactants undergo a lamellar-to-micellar phase transition at acidic pH. Evidence for a non-inverted membrane-destabilizing hexagonal phase of lipoplexes.

Luc Wasungu1, Marc C A Stuart, Marco Scarzello, Jan B F N Engberts, Dick Hoekstra.   

Abstract

The present study aims at a better understanding of the mechanism of transfection mediated by two sugar-based gemini surfactants GS1 and GS2. Previously, these gemini surfactants have been shown to be efficient gene vectors for transfection both in vitro and in vivo. Here, using Nile Red, a solvatochromic fluorescent probe, we investigated the phase behavior of these gemini surfactants in complexes with plasmid DNA, so-called lipoplexes. We found that these lipoplexes undergo a lamellar-to-non-inverted micellar phase transition upon decreasing the pH from neutral to mildly acidic. This normal (non-inverted) phase at acidic pH is confirmed by the colloidal stability of the lipoplexes as shown by turbidity measurements. We therefore propose a normal hexagonal phase, H(I), for the gemini surfactant lipoplexes at acidic endosomal pH. Thus, we suggest that besides an inverted hexagonal (H(II)) phase as reported for several transfection-potent cationic lipid systems, another type of non-inverted non-bilayer structure, different from H(II), may destabilize the endosomal membrane, necessary for cytosolic DNA delivery and ultimately, cellular transfection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16930530     DOI: 10.1016/j.bbamem.2006.06.019

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

Review 1.  Poly-N-acetyl glucosamine gel matrix as a non-viral delivery vector for DNA-based vaccination.

Authors:  Mohamed L Salem; Marina Demcheva; William E Gillanders; David J Cole; John N Vournakis
Journal:  Anticancer Res       Date:  2010-10       Impact factor: 2.480

2.  Urothelial endocytic vesicle recycling and lysosomal degradative pathway regulated by lipid membrane composition.

Authors:  E J Grasso; R O Calderón
Journal:  Histochem Cell Biol       Date:  2012-10-12       Impact factor: 4.304

Review 3.  Membrane lipids and proteins as modulators of urothelial endocytic vesicles pathways.

Authors:  E J Grasso; R O Calderón
Journal:  Histochem Cell Biol       Date:  2013-04-27       Impact factor: 4.304

4.  Bio-inspired supramolecular self-assembly towards soft nanomaterials.

Authors:  Yiyang Lin; Chuanbin Mao
Journal:  Front Mater Sci       Date:  2011-09-01       Impact factor: 2.765

5.  Nonionic surfactant vesicles for delivery of RNAi therapeutics.

Authors:  Orapan Paecharoenchai; Lesheng Teng; Bryant C Yung; Lirong Teng; Praneet Opanasopit; Robert J Lee
Journal:  Nanomedicine (Lond)       Date:  2013-11       Impact factor: 5.307

6.  Effect of spacer attachment sites and pH-sensitive headgroup expansion on cationic lipid-mediated gene delivery of three novel myristoyl derivatives.

Authors:  Michael Spelios; Sean Nedd; Nikita Matsunaga; Michalakis Savva
Journal:  Biophys Chem       Date:  2007-05-31       Impact factor: 2.352

7.  Biomaterials for mRNA delivery.

Authors:  Mohammad Ariful Islam; Emma K G Reesor; Yingjie Xu; Harshal R Zope; Bruce R Zetter; Jinjun Shi
Journal:  Biomater Sci       Date:  2015-08-17       Impact factor: 6.843

8.  Urinary bladder membrane permeability differentially induced by membrane lipid composition.

Authors:  Ernesto Javier Grasso; Reyna Olga Calderón
Journal:  Mol Cell Biochem       Date:  2009-05-03       Impact factor: 3.396

Review 9.  Gene delivery by cationic lipid vectors: overcoming cellular barriers.

Authors:  Inge S Zuhorn; Jan B F N Engberts; Dick Hoekstra
Journal:  Eur Biophys J       Date:  2006-09-22       Impact factor: 2.095

10.  Gemini alkyldeoxy-D-glucitolammonium salts as modern surfactants and microbiocides: synthesis, antimicrobial and surface activity, biodegradation.

Authors:  Bogumił Brycki; Adrianna Szulc
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.